We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
DP<sub>2</sub> antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment.
- Authors
Saunders, Ruth; Kaul, Himanshu; Berair, Rachid; Gonem, Sherif; Singapuri, Amisha; Sutcliffe, Amanda J.; Chachi, Latifa; Biddle, Michael S.; Kaur, Davinder; Bourne, Michelle; Pavord, Ian D.; Wardlaw, Andrew J.; Siddiqui, Salman H.; Kay, Richard A.; Brook, Bindi S.; Smallwood, Rod H.; Brightling, Christopher E.
- Abstract
Cellular and computational models and bronchial biopsies from asthma patients show that a DP2 antagonist reduces airway smooth muscle mass in asthma. Smoothing out muscle in asthma: Asthma is often treated with drugs that reduce airway inflammation. Saunders et al. now show that fevipiprant, a prostaglandin D2 type 2 receptor antagonist, reduced smooth muscle mass in bronchial biopsies from asthma patients. Computational simulations of an asthmatic airway predicted that this decrease in airway smooth muscle mass was due to both amelioration of inflammation observed in a prior clinical trial together with direct effects on migration of myofibroblasts. Treating smooth muscle cells from bronchial biopsies from asthma patients with fevipiprant in vitro revealed that the drug-induced decrease in airway smooth muscle mass may be due to reduced migration of myofibroblasts and fibrocytes. Increased airway smooth muscle mass, a feature of airway remodeling in asthma, is the strongest predictor of airflow limitation and contributes to asthma-associated morbidity and mortality. No current drug therapy for asthma is known to affect airway smooth muscle mass. Although there is increasing evidence that prostaglandin D2 type 2 receptor (DP2) is expressed in airway structural and inflammatory cells, few studies have addressed the expression and function of DP2 in airway smooth muscle cells. We report that the DP2 antagonist fevipiprant reduced airway smooth muscle mass in bronchial biopsies from patients with asthma who had participated in a previous randomized placebo-controlled trial. We developed a computational model to capture airway remodeling. Our model predicted that a reduction in airway eosinophilia alone was insufficient to explain the clinically observed decrease in airway smooth muscle mass without a concomitant reduction in the recruitment of airway smooth muscle cells or their precursors to airway smooth muscle bundles that comprise the airway smooth muscle layer. We experimentally confirmed that airway smooth muscle migration could be inhibited in vitro using DP2-specific antagonists in an airway smooth muscle cell culture model. Our analyses suggest that fevipiprant, through antagonism of DP2, reduced airway smooth muscle mass in patients with asthma by decreasing airway eosinophilia in concert with reduced recruitment of myofibroblasts and fibrocytes to the airway smooth muscle bundle. Fevipiprant may thus represent a potential therapy to ameliorate airway remodeling in asthma.
- Subjects
SMOOTH muscle; ASTHMA; BRONCHIAL diseases; OBSTRUCTIVE lung diseases; EOSINOPHILIA; MYOFIBROBLASTS
- Publication
Science Translational Medicine, 2019, Vol 11, Issue 479, pN.PAG
- ISSN
1946-6234
- Publication type
Article
- DOI
10.1126/scitranslmed.aao6451